Published in Obstet Gynecol on May 01, 2009
Concurrent chemoradiation for vaginal cancer. PLoS One (2013) 0.86
Prevention of cervical, vaginal, and vulval cancers: role of the quadrivalent human papillomavirus (6, 11, 16, 18) recombinant vaccine. Int J Womens Health (2010) 0.84
Definitive radiotherapy for primary vaginal cancer: correlation between treatment patterns and recurrence rate. J Radiat Res (2015) 0.81
Radiotherapy for carcinoma of the vagina. Immunocytochemical and cytofluorometric analysis of prognostic factors. Strahlenther Onkol (2013) 0.80
Primary vaginal cancer: role of MRI in diagnosis, staging and treatment. Br J Radiol (2015) 0.80
The utility and management of vaginal cytology after treatment for endometrial cancer. Obstet Gynecol (2013) 0.77
Primary Vaginal Melanoma, A Rare and Aggressive Entity. A Case Report and Review of the Literature. In Vivo (2017) 0.75
Definitive treatment of primary vaginal cancer with radiotherapy: multi-institutional retrospective study of the Korean Radiation Oncology Group (KROG 12-09). J Gynecol Oncol (2016) 0.75
[Grading of gynecological tumors : Current aspects]. Pathologe (2016) 0.75
Abdominal radical trachelectomy for vaginal cancer - A case report. Gynecol Oncol Rep (2017) 0.75
Cancer statistics, 2006. CA Cancer J Clin (2006) 30.71
Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med (1999) 9.16
Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol (2000) 6.06
Adenocarcinoma of the vagina in adolescence. A report of 7 cases including 6 clear-cell carcinomas (so-called mesonephromas). Cancer (1970) 2.44
A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol (2002) 1.90
The National Cancer Data Base report on cancer of the vagina. Cancer (1998) 1.69
Cancer incidence and mortality in the United States, 1973-77. Natl Cancer Inst Monogr (1981) 1.31
Descriptive epidemiology of vaginal cancer incidence and survival by race, ethnicity, and age in the United States. Cancer (2008) 1.12
An epidemiologic study of cancer of the cervix, vagina, and vulva based on the Third National Cancer Survey in the United States. Am J Obstet Gynecol (1977) 1.03
An analysis of 346 cases of clear cell adenocarcinoma of the vagina and cervix with emphasis on recurrence and survival. Gynecol Oncol (1979) 0.98
A 30-year experience in the management of primary carcinoma of the vagina: analysis of prognostic factors and treatment modalities. Gynecol Oncol (1995) 0.98
Vaginal cancers. Curr Opin Obstet Gynecol (2005) 0.91
Earlier detection of recurrent cancer of the uterine cervix by vaginal smear. Am J Obstet Gynecol (1952) 0.90
Invasive vaginal carcinoma: analysis of early-stage disease. Gynecol Oncol (1991) 0.90
Progress in gynecologic cancer research: the Gynecologic Oncology Group experience. Semin Oncol (2008) 0.85
Clinical and histopathologic factors related to prognosis in primary squamous cell carcinoma of the vagina. Int J Gynecol Cancer (2006) 0.84
Squamous carcinoma of the vagina: treatment, complications, and long-term follow-up. Gynecol Oncol (1985) 0.80
Vaginal cancer. Curr Treat Options Oncol (2002) 0.80
Early-stage vaginal carcinoma--an analysis of 70 patients. Int J Gynecol Cancer (2004) 0.79
Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res (2007) 3.97
Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst (2011) 2.84
Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res (2004) 2.80
Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. Cancer (2008) 2.56
Active smoking and the risk of estrogen receptor-positive and triple-negative breast cancer among women ages 20 to 44 years. Cancer (2014) 2.43
Disparities in breast cancer characteristics and outcomes by race/ethnicity. Breast Cancer Res Treat (2010) 2.36
Differences in colorectal carcinoma stage and survival by race and ethnicity. Cancer (2005) 2.26
The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations. Cancer (2010) 2.13
Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev (2005) 2.03
Racial and ethnic disparities in cervical cancer incidence rates in the United States, 1992-2003. Cancer Causes Control (2007) 1.92
Net risk reclassification p values: valid or misleading? J Natl Cancer Inst (2014) 1.86
Trends in treatment of advanced epithelial ovarian cancer in the Medicare population. Gynecol Oncol (2011) 1.77
Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol (2009) 1.77
Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol (2011) 1.74
Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer. Am J Obstet Gynecol (2005) 1.72
Use of complementary and alternative medicine among women with gynecologic cancers. Gynecol Oncol (2002) 1.72
Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder. Cancer (2006) 1.67
Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer. Cancer Epidemiol Biomarkers Prev (2011) 1.67
Disparities in access to lung transplantation for patients with cystic fibrosis by socioeconomic status. Am J Respir Crit Care Med (2012) 1.64
Genetic polymorphisms in the catechol estrogen metabolism pathway and breast cancer risk. Cancer Epidemiol Biomarkers Prev (2009) 1.62
Long-term statin use and risk of ductal and lobular breast cancer among women 55 to 74 years of age. Cancer Epidemiol Biomarkers Prev (2013) 1.59
Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev (2008) 1.53
Combining a symptoms index with CA 125 to improve detection of ovarian cancer. Cancer (2008) 1.53
Feasibility of including cellular telephone numbers in random digit dialing for epidemiologic case-control studies. Am J Epidemiol (2010) 1.52
Intrapartum fever and chorioamnionitis as risks for encephalopathy in term newborns: a case-control study. Dev Med Child Neurol (2008) 1.51
Alternate molecular genetic pathways in ovarian carcinomas of common histological types. Hum Pathol (2007) 1.49
Reported referral for genetic counseling or BRCA 1/2 testing among United States physicians: a vignette-based study. Cancer (2011) 1.47
An evaluation of cervical cancer in women age sixty and over. Gynecol Oncol (2008) 1.43
Impact of freeze-thaw cycles and storage time on plasma samples used in mass spectrometry based biomarker discovery projects. Cancer Inform (2005) 1.43
Adequate staging for uterine cancer can be performed through Pfannenstiel incisions. Gynecol Oncol (2003) 1.41
Reproductive history and risk of three breast cancer subtypes defined by three biomarkers. Cancer Causes Control (2010) 1.33
Breast cancer characteristics and outcomes among Hispanic Black and Hispanic White women. Breast Cancer Res Treat (2012) 1.32
Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial. Gynecol Oncol (2005) 1.31
Effects of blood collection conditions on ovarian cancer serum markers. PLoS One (2007) 1.27
Robotic surgery in gynecologic oncology: program initiation and outcomes after the first year with comparison with laparotomy for endometrial cancer staging. Am J Obstet Gynecol (2008) 1.24
Breast density, body mass index, and risk of tumor marker-defined subtypes of breast cancer. Ann Epidemiol (2012) 1.16
Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer. Breast Cancer Res Treat (2011) 1.16
Insurance status and risk of cancer mortality among adolescents and young adults. Cancer (2014) 1.15
Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer. Gynecol Oncol (2008) 1.15
Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera. Cancer Prev Res (Phila) (2012) 1.15
Smoking and alcohol consumption in relation to risk of triple-negative breast cancer in a cohort of postmenopausal women. Cancer Causes Control (2011) 1.15
Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J Clin Oncol (2004) 1.15
Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk. Breast Cancer Res Treat (2010) 1.14
Trends in the incidence rates of nasopharyngeal carcinoma among Chinese Americans living in Los Angeles County and the San Francisco metropolitan area, 1992-2002. Am J Epidemiol (2005) 1.13
Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol Cancer (2009) 1.12
Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. Am J Obstet Gynecol (2006) 1.12
Vignette-based study of ovarian cancer screening: do U.S. physicians report adhering to evidence-based recommendations? Ann Intern Med (2012) 1.12
Self-assessment of resident surgical skills: is it feasible? Am J Obstet Gynecol (2005) 1.11
Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study. Cancer (2011) 1.11
Migraine in postmenopausal women and the risk of invasive breast cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.09
Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contralateral breast cancer. J Natl Cancer Inst (2011) 1.08
Adjuvant high dose rate vaginal brachytherapy as treatment of stage I and II endometrial carcinoma. Obstet Gynecol (2002) 1.07
Surgical outcomes in gynecologic oncology in the era of robotics: analysis of first 1000 cases. Am J Obstet Gynecol (2011) 1.06
MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma: Relationship to CDKN1B, CDKNIC and overall survival. Genes Chromosomes Cancer (2010) 1.05
Patterns of spread and recurrence of sex cord-stromal tumors of the ovary. Gynecol Oncol (2011) 1.04
Population-based estimates of the relation between breast cancer risk, tumor subtype, and family history. Breast Cancer Res Treat (2008) 1.00
Detection of elevated plasma levels of epidermal growth factor receptor before breast cancer diagnosis among hormone therapy users. Cancer Res (2010) 0.98
Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study. Gynecol Oncol (2008) 0.98
A new curriculum for hysteroscopy training as demonstrated by an objective structured assessment of technical skills (OSATS). Am J Obstet Gynecol (2005) 0.97
Dangerous combinations: Ingestible CAM supplement use during chemotherapy in patients with ovarian cancer. J Altern Complement Med (2013) 0.96
A six-year study of surgical teaching and skills evaluation for obstetric/gynecologic residents in porcine and inanimate surgical models. Am J Obstet Gynecol (2005) 0.96
Pelvic exenteration in the age of modern chemoradiation. Gynecol Oncol (2011) 0.95
Risk factors for ductal, lobular, and mixed ductal-lobular breast cancer in a screening population. Cancer Epidemiol Biomarkers Prev (2010) 0.95
Neoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancer. Gynecol Oncol (2011) 0.95
AACR Cancer Progress Report 2013. Clin Cancer Res (2013) 0.95
Survival differences by race in nasopharyngeal carcinoma. Am J Epidemiol (2006) 0.94
Use of antihypertensive medications and breast cancer risk. Cancer Causes Control (2012) 0.94
Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol (2009) 0.93
Relationship between menopausal symptoms and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev (2011) 0.93
Oral contraceptives and breast cancer risk overall and by molecular subtype among young women. Cancer Epidemiol Biomarkers Prev (2014) 0.92
Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas. Genes Chromosomes Cancer (2007) 0.92
Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer. Breast Cancer Res Treat (2012) 0.92
Ovarian cancer in the elderly: outcomes with neoadjuvant chemotherapy or primary cytoreduction. Gynecol Oncol (2010) 0.92
Identification of ovarian cancer symptoms in health insurance claims data. J Womens Health (Larchmt) (2010) 0.91
Antidepressant use and breast cancer risk. Breast Cancer Res Treat (2005) 0.90
Racial/ethnic differences in use and duration of adjuvant hormonal therapy for breast cancer in the women's health initiative. Cancer Epidemiol Biomarkers Prev (2012) 0.90
Estrogen-related genes and their contribution to racial differences in breast cancer risk. Cancer Causes Control (2012) 0.89
Uterine papillary serous carcinoma: what have we learned over the past quarter century? Gynecol Oncol (2005) 0.89
Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage. Breast Cancer Res Treat (2014) 0.88
Glassy cell carcinoma of the cervix revisited. Gynecol Oncol (2002) 0.88
Feasibility study for collection of HER2 data by National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program central cancer registries. Cancer Epidemiol Biomarkers Prev (2010) 0.88
Trends in distant-stage breast, colorectal, and prostate cancer incidence rates from 1992 to 2004: potential influences of screening and hormonal factors. Horm Cancer (2010) 0.87
Reproductive factors, age at maximum height, and risk of three histologic types of breast cancer. Cancer Epidemiol Biomarkers Prev (2008) 0.87
Risk of epithelial ovarian cancer in relation to use of antidepressants, benzodiazepines, and other centrally acting medications. Cancer Causes Control (2002) 0.86
Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma. Gynecol Oncol (2006) 0.85
Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly. Obstet Gynecol (2011) 0.85
Concordant release of glycolysis proteins into the plasma preceding a diagnosis of ER+ breast cancer. Cancer Res (2012) 0.85
Re: "studies with low response proportions may be less biased than studies with high response proportions". Am J Epidemiol (2005) 0.84
Temporal trends in incidence and mortality rates for colorectal cancer by tumor location: 1975-2007. Am J Public Health (2012) 0.84
Timing of menarche and first birth in relation to risk of breast cancer in A-bomb survivors. Cancer Epidemiol Biomarkers Prev (2010) 0.84
Examination of ancestral informative markers and self-reported race with tumor characteristics of breast cancer among Black and White women. Breast Cancer Res Treat (2012) 0.84
Weekly gemcitabine and cisplatin in combination with pelvic radiation in the primary therapy of cervical cancer: a phase I trial of the Puget Sound Oncology Consortium. Gynecol Oncol (2005) 0.83
Value of symptom-triggered diagnostic evaluation for ovarian cancer. Obstet Gynecol (2014) 0.82
Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer. Gynecol Oncol (2009) 0.82
FOXP3+ regulatory T-cells are abundant in vulvar Paget's disease and are associated with recurrence. Gynecol Oncol (2011) 0.82
Height, body mass index (BMI), BMI change, and the risk of estrogen receptor-positive, HER2-positive, and triple-negative breast cancer among women ages 20 to 44 years. Cancer (2014) 0.82
Microparticles from ovarian carcinomas are shed into ascites and promote cell migration. Int J Gynecol Cancer (2012) 0.81
Involvement in decision-making about treatment and ovarian cancer survivor quality of life. Gynecol Oncol (2011) 0.81